POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Schizoaffective Disorder Clinical Trial

Official title:

POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01450514
• Other study ID #: PNB02-C201
• Secondary ID: 2011-004494-81
• Status: Completed
• Phase: Phase 2
• First received: October 7, 2011
• Last updated: November 18, 2014
• Start date: March 2012
• Est. completion date: December 2012

Study information

• Verified date: November 2014
• Source: PharmaNeuroBoost N.V.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or paliperidone (PAL) on functional MRI tests and clinical outcome of chronic schizophrenic patients with residual, so-called 'positive' symptoms, as well as on cognition, motivation, subjective well-being of patients, negative symptoms, general psychopathological symptoms and safety/tolerability.

Description:

This exploratory study of 7 weeks was intended to be performed in 40 to 60 patients in up to 10 centers in Belgium. In a subset of patients, the 6-week treatment phase will be preceded by a single-dose cross-over phase with 1 week of wash-out. While the objective of the study, due to its exploratory design, is to assess any effect of the study medication on MRI or clinical outcome, the study medication is expected to improve the residual (remaining) positive symptom(s) of patients. In addition, genetic and pharmacokinetic testing may be performed to learn more about the disorder and its treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: December 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.

• Patient understands the investigational nature of the trial and is willing and able to comply with the trial requirements.

• Patient is male or female, aged 18-65 years.

• Patients has Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria. Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI)

• Patient is being treated during at least 12 weeks with a stable dosage of either risperidone depot of 12.5-50mg IM every 2 weeks, paliperidone depot of 25-100mg IM every 4 weeks, risperidone oral administration of 2-6 mg/d, or paliperidone oral administration of 4-12 mg/d

• Patient has a CGI-S score of 3 (mildly ill) or more at baseline.

• Patient has a score of 4 or more on at least 1 item of the positive PANSS subscale (residual symptoms).

Exclusion Criteria:

• Acute exacerbation of schizophrenic or schizoaffective disorder during the past 12 weeks.

• Documented debility or an IQ below 85.

• Comorbid axis 1 conditions (including anxiety disorders, eating disorders, impulse control disorders) requiring drug treatment over the previous 12 weeks.

• Patient has taken, in the past 6 weeks prior to randomization, any newly initiated psychoactive drug.

• Patient was withdrawn from psychoactive drug treatment in the past week or within a period shorter than 5x the elimination half-life of any psychoactive drug. Withdrawal of any prior antipsychotic treatment should not have occurred within 6 weeks prior to baseline.

• Concomitant treatment with any additional antipsychotic drug at a therapeutic dosage, diuretics, QT prolongation drugs, or dopamine agonists.

• Formal cognitive psychotherapy initiated during study treatment or within 6 weeks prior to randomization.

• Patient has any other medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the patient's ability to participate in this trial or that would interfere with trial assessments.

• Patient with a DSM-IV alcohol or substance dependence diagnosis (within the last 6 months), an alcohol or substance abuse diagnosis (within the last month) or having a positive standard screen for alcohol or drugs (including benzodiazepines and opioids).

• 'Any concomitant psychoactive treatment (including psychotherapy)' or 'Patient received, in the 6 weeks prior to randomization any newly prescribed psychoactive drug'.

• Patient is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or who does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Schizophrenia
• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia

Intervention

Drug:
• Pipamperone
15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
• Placebo
matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL

Locations

Country	Name	City	State
Belgium	University Psychiatric Institute Sint-Jozef	Kortenberg

Sponsors (1)

Lead Sponsor	Collaborator
PharmaNeuroBoost N.V.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in functional MRI tests	MRI = Magnetic Resonance Imaging Functional tests performed during MRI include the N-Back Test and the Monetary Incentive Delay (MID) Task Test	1 day, 2 weeks and 6 weeks after study treatment start	No
Secondary	Change from baseline in residual PANSS item(s)	PANSS = Positive and Negative Syndrome Scale	2 weeks and 6 weeks after study treatment start	No
Secondary	Change from baseline in SWN score and subitem scores	SWN = Subjective Well-being under Neuroleptics questionnaire	2 weeks and 6 weeks after study treatment start	No
Secondary	Change from baseline in IMI-SR score and subitem scores	IMI-SR = Intrinsic Motivation Inventory for Schizophrenia Research (questionnaire)	2 weeks and 6 weeks after study treatment start	No
Secondary	CGI-I score	CGI-I = Clinical Global Impression if Improvement	2 weeks and 6 weeks after study treatment start	No
Secondary	Change from baseline in BARS total and subitem scores	BARS = Barnes Akathisia Rating Scale	6 weeks after study treatment start	Yes
Secondary	Change from baseline in BACS score and subitem scores	BACS = Brief Assessment of Cognition Scale	1 day, 2 weeks and 6 weeks after study treatment start	No